BiotechTube

GP40141 + Nplate

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacodynamics

Conditions

Pharmacodynamics, Pharmacokinetics, Bioequivalence

Trial Timeline

Jun 3, 2022 → Sep 30, 2024

NCT ID
NCT05652595

About GP40141 + Nplate

GP40141 + Nplate is a phase 1 stage product being developed by GEROPHARM for Pharmacodynamics. The current trial status is unknown. This product is registered under clinical trial identifier NCT05652595. Target conditions include Pharmacodynamics, Pharmacokinetics, Bioequivalence.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05652595Phase 1UNKNOWN

Competing Products

6 competing products in Pharmacodynamics

See all competitors
ProductCompanyStageHype Score
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tabletsAstraZenecaPhase 1
33
D961H + OmeprazoleAstraZenecaPhase 1
33
Dienogest (81150037) + Dienogest (81150231) + Dienogest (SH T00660A) + Dienogest (81150746)BayerPhase 1
30
5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F)IdorsiaPhase 1
28
VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)VaxartPhase 1
25

Other Products from GEROPHARM

Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous SolutionPhase 3
69
GP404141 + NplatePhase 3
69
GP40081 + NovoMix 30Phase 3
69
GP40071 + NovoRapid® Penfill®Phase 3
69
GP40321 + Apidra® SoloStar® + RinGlar®Phase 3
69